COVID-19 and biologics for psoriasis: A high-epidemic area experience—Bergamo, Lombardy, Italy - 19/06/20
Doi : 10.1016/j.jaad.2020.04.165
Andrea Carugno, MD a, ⁎ 
, Daniele Mario Gambini, MD, PhD a, Francesca Raponi, MD a, Pamela Vezzoli, MD, PhD a, Andrea Gustavo C. Locatelli, MD a, Marco Di Mercurio, MD a, Elisa Robustelli Test, MD b, Paolo Sena, MD a
, Daniele Mario Gambini, MD, PhD a, Francesca Raponi, MD a, Pamela Vezzoli, MD, PhD a, Andrea Gustavo C. Locatelli, MD a, Marco Di Mercurio, MD a, Elisa Robustelli Test, MD b, Paolo Sena, MD a a Dermatology Unit, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII Hospital, Lombardy, Bergamo
b Dermatology Clinic, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy
∗Correspondence to: Andrea Carugno, MD, Dermatology Unit, ASST Papa Giovanni XXIII, Hospital, Piazza OMS, 1, 24127 Bergamo (BG), ItalyDermatology UnitASST Papa Giovanni XXIIIHospitalPiazza OMS, 1Bergamo (BG)24127Italy
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
|
| IRB approval status: The ethical committee was notified of the observational study. |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 83 - N° 1
P. 292-294 - juillet 2020 Retour au numéro
Article précédent
- Clinical considerations for managing dermatology patients on systemic immunosuppressive or biologic therapy, or both, during the COVID-19 pandemic
- Daniela P. Sanchez, Robert S. Kirsner, Hadar Lev-Tov
- Perspectives on the recommendations for skin cancer management during the COVID-19 pandemic
- Larisa J. Geskin, Megan H. Trager, Sumaira Z. Aasi, David R. Bickers, Richard D. Carvajal, Paul Nghiem, Bret Taback, Nathalie C. Zeitouni, Faramarz H. Samie
Bienvenue sur EM-consulte, la référence des professionnels de santé.